TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
MRNA

Moderna Inc

Healthcare · Biotechnology

198.90$ +2.1% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Moderna Inc (MRNA). It shows which part of the business is growing — and which one is holding it back.

Remaining performance obligations

Remaining performance obligations are the part of the business already sold but not yet delivered and therefore not yet booked as revenue. In subscription and project businesses it points the way earlier than revenue does.

Remaining performance obligations — MRNA
As of Remaining performance obligations
Q4 2020 $87.2M
Q3 2020 $104.9M
Q2 2020 $104.9M
Q1 2020 $278.8M
Q4 2019 $249.5M
Q3 2019 $261.0M
Q2 2019 $268.2M
Q1 2019 $279.5M

Operating metrics

Operating metrics are the figures a company uses to measure its own business — customer counts, stores, deliveries or the churn rate. None of them appear in the financial statements, and they often explain earlier than revenue does why revenue is moving.

Operating metrics — MRNA
Metric Q2 2025 Q3 2025 Q1 2026 Q2 2026
Headquarters (Moderna Science Center) square footage 462,000 462,000 462,000 462,000 +0.0%
Number of development programs 39 40 35 36 -7.7%
Number of development candidates 30 30 25 26 -13.3%

These metrics are not part of the financial statements; they sit in the narrative text of the filings. We read them out of the SEC filings using artificial intelligence and check every single figure against the original passage in the report; anything that is not found there verbatim is discarded. Source: SEC EDGAR (annual and quarterly reports, 10-K/10-Q).

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?